

Masoud H Manjili

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1202387/publications.pdf>

Version: 2024-02-01

108
papers

5,198
citations

87843

38
h-index

91828

69
g-index

111
all docs

111
docs citations

111
times ranked

8669
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic Cancer Vaccines. <i>Advances in Cancer Research</i> , 2013, 119, 421-475.	1.9	450
2	Immune-Induced Epithelial to Mesenchymal Transition <i>In vivo</i> Generates Breast Cancer Stem Cells. <i>Cancer Research</i> , 2009, 69, 2887-2895.	0.4	369
3	Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. <i>International Immunopharmacology</i> , 2009, 9, 900-909.	1.7	307
4	Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. <i>Carcinogenesis</i> , 2015, 36, S254-S296.	1.3	239
5	CD44 ⁺ /CD24 ^{low} cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. <i>Human Pathology</i> , 2012, 43, 364-373.	1.1	227
6	GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1 ⁺ bone marrow progenitor cells into myeloid-derived suppressor cells. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 39-49.	1.1	179
7	Tumor immunoeediting and immunosculpting pathways to cancer progression. <i>Seminars in Cancer Biology</i> , 2007, 17, 275-287.	4.3	167
8	A signature of immune function genes associated with recurrence-free survival in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 871-880.	1.1	166
9	COVID-19 as an Acute Inflammatory Disease. <i>Journal of Immunology</i> , 2020, 205, 12-19.	0.4	133
10	Human T cells express CD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor function. <i>Journal of Translational Medicine</i> , 2009, 7, 89.	1.8	130
11	HSP110-HER2/neu Chaperone Complex Vaccine Induces Protective Immunity Against Spontaneous Mammary Tumors in HER-2/neu Transgenic Mice. <i>Journal of Immunology</i> , 2003, 171, 4054-4061.	0.4	107
12	Heat shock proteins as vaccine adjuvants in infections and cancer. <i>Drug Discovery Today</i> , 2006, 11, 534-540.	3.2	95
13	HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses. <i>European Journal of Immunology</i> , 2007, 37, 675-685.	1.6	92
14	Tumor Dormancy and Relapse: From a Natural Byproduct of Evolution to a Disease State. <i>Cancer Research</i> , 2017, 77, 2564-2569.	0.4	87
15	An immunologic portrait of cancer. <i>Journal of Translational Medicine</i> , 2011, 9, 146.	1.8	83
16	Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients. <i>Journal of Translational Medicine</i> , 2013, 11, 145.	1.8	82
17	The microbiome and breast cancer: a review. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 493-496.	1.1	82
18	Cutting Edge: Mast Cells Critically Augment Myeloid-Derived Suppressor Cell Activity. <i>Journal of Immunology</i> , 2012, 189, 511-515.	0.4	81

#	ARTICLE	IF	CITATIONS
19	Tumor Cell Dormancy: Threat or Opportunity in the Fight against Cancer. <i>Cancers</i> , 2019, 11, 1207.	1.7	75
20	IFN- γ orchestrates tumor elimination, tumor dormancy, tumor escape, and progression. <i>Journal of Leukocyte Biology</i> , 2018, 103, 1219-1223.	1.5	74
21	Development of a recombinant HSP110-HER-2/neu vaccine using the chaperoning properties of HSP110. <i>Cancer Research</i> , 2002, 62, 1737-42.	0.4	67
22	Radiofrequency thermal ablation of breast tumors combined with intralesional administration of IL-7 and IL-15 augments anti-tumor immune responses and inhibits tumor development and metastasis. <i>Breast Cancer Research and Treatment</i> , 2009, 114, 423-431.	1.1	56
23	Fractal Organization of the Human T Cell Repertoire in Health and after Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 366-377.	2.0	55
24	Chaperoning Function of Stress Protein grp170, a Member of the hsp70 Superfamily, Is Responsible for its Immunoadjuvant Activity. <i>Cancer Research</i> , 2006, 66, 1161-1168.	0.4	54
25	Human mast cells present antigen to autologous CD4+ T cells. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 311-321.e10.	1.5	52
26	Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 941-953.	2.0	51
27	The Roles of Autophagy and Senescence in the Tumor Cell Response to Radiation. <i>Radiation Research</i> , 2020, 194, 103.	0.7	51
28	IL-7+IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 359-369.	1.1	49
29	Targeting the Immunoregulator SRA/CD204 Potentiates Specific Dendritic Cell Vaccine-Induced T-cell Response and Antitumor Immunity. <i>Cancer Research</i> , 2011, 71, 6611-6620.	0.4	49
30	In silico Derivation of HLA-Specific Alloreactivity Potential from Whole Exome Sequencing of Stem-Cell Transplant Donors and Recipients: Understanding the Quantitative Immunobiology of Allogeneic Transplantation. <i>Frontiers in Immunology</i> , 2014, 5, 529.	2.2	48
31	Whole exome sequencing to estimate alloreactivity potential between donors and recipients in stem cell transplantation. <i>British Journal of Haematology</i> , 2014, 166, 566-570.	1.2	47
32	Immunotherapy of cancer using heat shock proteins. <i>Frontiers in Bioscience - Landmark</i> , 2002, 7, d43.	3.0	45
33	Autophagy-deficient breast cancer shows early tumor recurrence and escape from dormancy. <i>Oncotarget</i> , 2018, 9, 22113-22122.	0.8	45
34	Chemical compounds from anthropogenic environment and immune evasion mechanisms: potential interactions. <i>Carcinogenesis</i> , 2015, 36, S111-S127.	1.3	43
35	DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1061-1073.	2.0	40
36	Hsp110 over-expression increases the immunogenicity of the murine CT26 colon tumor. <i>Cancer Immunology, Immunotherapy</i> , 2002, 51, 311-319.	2.0	39

#	ARTICLE	IF	CITATIONS
37	Signatures Associated with Rejection or Recurrence in HER-2/positive Mammary Tumors. <i>Cancer Research</i> , 2008, 68, 2436-2446.	0.4	39
38	Activated NKT Cells and NK Cells Render T Cells Resistant to Myeloid-Derived Suppressor Cells and Result in an Effective Adoptive Cellular Therapy against Breast Cancer in the FVB/N202 Transgenic Mouse. <i>Journal of Immunology</i> , 2011, 187, 708-717.	0.4	39
39	Tumor-reactive immune cells protect against metastatic tumor and induce immunoeediting of indolent but not quiescent tumor cells. <i>Journal of Leukocyte Biology</i> , 2016, 100, 625-635.	1.5	39
40	The Inherent Premise of Immunotherapy for Cancer Dormancy. <i>Cancer Research</i> , 2014, 74, 6745-6749.	0.4	38
41	Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity. <i>British Journal of Haematology</i> , 2012, 158, 700-711.	1.2	37
42	HSP110 induces "danger signals" upon interaction with antigen presenting cells and mouse mammary carcinoma. <i>Immunobiology</i> , 2005, 210, 295-303.	0.8	36
43	Low-Dose Mixture Hypothesis of Carcinogenesis Workshop: Scientific Underpinnings and Research Recommendations. <i>Environmental Health Perspectives</i> , 2017, 125, 163-169.	2.8	35
44	Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 1565-1576.	2.0	33
45	Distinct signatures of the immune responses in low risk versus high risk neuroblastoma. <i>Journal of Translational Medicine</i> , 2011, 9, 170.	1.8	33
46	Coordinated Upregulation of Mitochondrial Biogenesis and Autophagy in Breast Cancer Cells: The Role of Dynamin Related Protein-1 and Implication for Breast Cancer Treatment. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-10.	1.9	31
47	Prostate-derived Ets transcription factor (PDEF) is a potential prognostic marker in patients with prostate cancer. <i>Prostate</i> , 2011, 71, 1178-1188.	1.2	30
48	Dynamical System Modeling to Simulate Donor T Cell Response to Whole Exome Sequencing-Derived Recipient Peptides Demonstrates Different Alloreactivity Potential in HLA-Matched and -Mismatched Donor-Recipient Pairs. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 850-861.	2.0	29
49	Dynamical System Modeling of Immune Reconstitution after Allogeneic Stem Cell Transplantation Identifies Patients at Risk for Adverse Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1237-1245.	2.0	28
50	Heat Shock Proteins and Scavenger Receptors: Role in Adaptive Immune Responses. <i>Immunological Investigations</i> , 2005, 34, 325-342.	1.0	27
51	IFN- γ Is a Key Determinant of CD8+ T Cell-Mediated Tumor Elimination or Tumor Escape and Relapse in FVB Mouse. <i>PLoS ONE</i> , 2013, 8, e82544.	1.1	27
52	Cancer immunotherapy and heat-shock proteins: promises and challenges. <i>Expert Opinion on Biological Therapy</i> , 2004, 4, 363-373.	1.4	26
53	Prostate-derived Ets transcription factor as a favorable prognostic marker in ovarian cancer patients. <i>International Journal of Cancer</i> , 2008, 123, 1376-1384.	2.3	26
54	Signatures of tumor-immune interactions as biomarkers for breast cancer prognosis. <i>Future Oncology</i> , 2012, 8, 703-711.	1.1	26

#	ARTICLE	IF	CITATIONS
55	Suppression of antigen-specific CD4+ T cell activation by SRA/CD204 through reducing the immunostimulatory capability of antigen-presenting cell. <i>Journal of Molecular Medicine</i> , 2012, 90, 413-426.	1.7	26
56	Evolution of Our Understanding of Myeloid Regulatory Cells: From MDSCs to Mregs. <i>Frontiers in Immunology</i> , 2014, 5, 303.	2.2	25
57	Stem Cell Transplantation as a Dynamical System: Are Clinical Outcomes Deterministic?. <i>Frontiers in Immunology</i> , 2014, 5, 613.	2.2	25
58	Immunoadjuvant chaperone, GRP170, induces "danger signals" upon interaction with dendritic cells. <i>Immunology and Cell Biology</i> , 2006, 84, 203-208.	1.0	24
59	Danger signals and nonself entity of tumor antigen are both required for eliciting effective immune responses against HER-2/neu positive mammary carcinoma: implications for vaccine design. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1391-1398.	2.0	23
60	Revisiting cancer immunoediting by understanding cancer immune complexity. <i>Journal of Pathology</i> , 2011, 224, 5-9.	2.1	23
61	Heat shock proteins HSP70 and GP96: structural insights. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 339-346.	2.0	21
62	Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce "danger signals". <i>Breast Cancer Research and Treatment</i> , 2006, 96, 233-241.	1.1	20
63	Distinct Oligoclonal T Cells Are Associated With Graft Versus Host Disease After Stem-Cell Transplantation. <i>Transplantation</i> , 2012, 93, 949-957.	0.5	20
64	Phenotypic Plasticity of MDSC in Cancers. <i>Immunological Investigations</i> , 2012, 41, 711-721.	1.0	20
65	Peripheral blood mononuclear cells of patients with breast cancer can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 45-57.	1.1	20
66	Multifaceted functions of chronic inflammation in regulating tumor dormancy and relapse. <i>Seminars in Cancer Biology</i> , 2022, 78, 17-22.	4.3	19
67	Distinct hepatic immunological patterns are associated with the progression or inhibition of hepatocellular carcinoma. <i>Cell Reports</i> , 2022, 38, 110454.	2.9	19
68	Development of cancer vaccines using autologous and recombinant high molecular weight stress proteins. <i>Methods</i> , 2004, 32, 13-20.	1.9	18
69	CD4+ T cells inhibit the neu-specific CD8+ T-cell exhaustion during the priming phase of immune responses against breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 385-394.	1.1	18
70	Tumor escape and progression of HER-2/neu negative breast cancer under immune pressure. <i>Journal of Translational Medicine</i> , 2011, 9, 35.	1.8	17
71	Role of Tregs in Cancer Dormancy or Recurrence. <i>Immunological Investigations</i> , 2016, 45, 759-766.	1.0	17
72	The premise of personalized immunotherapy for cancer dormancy. <i>Oncogene</i> , 2020, 39, 4323-4330.	2.6	17

#	ARTICLE	IF	CITATIONS
73	Favorable Outcomes in Patients with High Donor-Derived T Cell Count after In Vivo T Cell-Depleted Reduced-Intensity Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 794-804.	2.0	14
74	The Role of Tyk2 in Regulation of Breast Cancer Growth. <i>Journal of Interferon and Cytokine Research</i> , 2011, 31, 671-677.	0.5	13
75	Adaptive Immune Responses Associated with Breast Cancer Relapse. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2012, 60, 345-350.	1.0	13
76	Longitudinal studies can identify distinct inflammatory cytokines associated with the inhibition or progression of liver cancer. <i>Liver International</i> , 2020, 40, 468-472.	1.9	13
77	Adoptive cellular therapy of cancer: exploring innate and adaptive cellular crosstalk to improve anti-tumor efficacy. <i>Future Oncology</i> , 2014, 10, 1779-1794.	1.1	12
78	A Theoretical Basis for the Efficacy of Cancer Immunotherapy and Immunogenic Tumor Dormancy: The Adaptation Model of Immunity. <i>Advances in Cancer Research</i> , 2018, 137, 17-36.	1.9	12
79	The adaptation model of immunity. <i>Immunotherapy</i> , 2014, 6, 59-70.	1.0	11
80	Conditioning neoadjuvant therapies for improved immunotherapy of cancer. <i>Biochemical Pharmacology</i> , 2017, 145, 12-17.	2.0	11
81	Determining the Quantitative Principles of T Cell Response to Antigenic Disparity in Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2018, 9, 2284.	2.2	11
82	Local and distant tumor dormancy during early stage breast cancer are associated with the predominance of infiltrating T effector subsets. <i>Breast Cancer Research</i> , 2020, 22, 116.	2.2	11
83	Tumour secreted grp170 chaperones full-length protein substrates and induces an adaptive anti-tumour immune response in vivo. <i>International Journal of Hyperthermia</i> , 2010, 26, 366-375.	1.1	10
84	HLA-DR expression on myeloid cells is a potential prognostic factor in patients with high-risk neuroblastoma. <i>Oncolimmunology</i> , 2013, 2, e26616.	2.1	9
85	Etiology of GVHD: Alloreactivity or Impaired Cellular Adaptation?. <i>Immunological Investigations</i> , 2014, 43, 851-857.	1.0	9
86	Cancer immunotherapy. <i>Oncolimmunology</i> , 2012, 1, 201-204.	2.1	8
87	Immunotherapy of Cancer: Reprogramming Tumor-Immune Crosstalk. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-8.	3.3	8
88	Pattern recognition of tumor dormancy and relapse beyond cell-intrinsic and cell-extrinsic pathways. <i>Seminars in Cancer Biology</i> , 2022, 78, 1-4.	4.3	8
89	Adoptive cell therapy of prostate cancer using female mice-derived T cells that react with prostate antigens. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 349-360.	2.0	7
90	On the organization of human T-cell receptor loci: log-periodic distribution of T-cell receptor gene segments. <i>Journal of the Royal Society Interface</i> , 2016, 13, 20150911.	1.5	6

#	ARTICLE	IF	CITATIONS
91	Immunotherapy of cancer: targeting cancer during active disease or during dormancy?. Immunotherapy, 2017, 9, 943-949.	1.0	6
92	Does HER2/neu antigen loss in metastatic breast tumors occur under immune pressure?. International Journal of Cancer, 2008, 123, 1476-1477.	2.3	5
93	Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatins and the Common Gamma Chain Cytokines Formulation. Journal of Visualized Experiments, 2011, , .	0.2	5
94	Gr1 ^{low} CD11b ^{low} MHCII ⁺ myeloid cells boost T cell anti-tumor efficacy. Journal of Leukocyte Biology, 2018, 104, 1215-1228.	1.5	5
95	Engineering T Cells to Express Tumoricidal MDA-7/IL24 Enhances Cancer Immunotherapy. Cancer Research, 2021, 81, 2429-2441.	0.4	5
96	Role of Epigenetic Modification and Immunomodulation in a Murine Prostate Cancer Model. Prostate, 2017, 77, 361-373.	1.2	4
97	Come forth 1E10 anti-idiotypic vaccine: Delivering the promise to immunotherapy of small cell lung cancer. Cancer Biology and Therapy, 2007, 6, 151-152.	1.5	3
98	Prospects in cancer immunotherapy: treating advanced stage disease or preventing tumor recurrence?. Discovery Medicine, 2015, 19, 427-31.	0.5	3
99	Comment on "Cutting Edge: CD8 ⁺ T Cell Priming in the Absence of NK Cells Leads to Enhanced Memory Responses". Journal of Immunology, 2011, 186, 6071.1-6071.	0.4	2
100	Tumor Escape and Progression under Immune Pressure. Clinical and Developmental Immunology, 2012, 2012, 1-2.	3.3	2
101	Fractal Organization of the Human T Cell Repertoire in Health and Following Stem Cell Transplantation. Blood, 2012, 120, 4193-4193.	0.6	2
102	Immune Regulatory Function of Tregs. Immunological Investigations, 2016, 45, 708-711.	1.0	1
103	Whole Exome Sequencing To Estimate Alloreactivity Potential Between Donors and Recipients In Stem Cell Transplantation. Blood, 2013, 122, 150-150.	0.6	1
104	Regulation of auto-antibody production by persisting auto-immune complexes on follicular dendritic cells. Annals of the Rheumatic Diseases, 2012, 71, A38.1-A38.	0.5	0
105	Multi-therapeutic potential of autoantibodies induced by immune complexes trapped on follicular dendritic cells. Human Vaccines and Immunotherapeutics, 2013, 9, 2434-2444.	1.4	0
106	Favorable Outcomes in Patients with High Donor-Derived T Cell Count Following In Vivo T Cell Depleted Reduced Intensity Allogeneic Stem Cell Transplantation. Blood, 2011, 118, 3043-3043.	0.6	0
107	Adaptive Immunotherapy In Multiple Myeloma: Epigenetic Modification and Immunomodulation by Sequential Azacitidine and Lenalidomide to Generate Cancer Testis Antigen Specific Cellular Immune Response. Blood, 2011, 118, 2926-2926.	0.6	0
108	Cancer immunotherapy: Identifying cancer testis antigen peptides to enhance antitumor response.. Journal of Clinical Oncology, 2022, 40, e20022-e20022.	0.8	0